- Home
- ANSC vs ASMB Comparison
ANSC vs ASMB Comparison
Compare ANSC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANSC | ASMB |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.1M | 442.9M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | ANSC | ASMB |
|---|---|---|
| Price | $11.44 | $27.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | 23.5K | ★ 259.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | $55.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.84 | $16.90 |
| 52 Week High | $11.45 | $39.71 |
Technical Indicators
Market Signals| Indicator | ANSC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 61.90 | 54.23 |
| Support Level | $11.38 | $26.18 |
| Resistance Level | $11.45 | $31.21 |
| Average True Range (ATR) | 0.01 | 1.75 |
| MACD | -0.00 | 0.33 |
| Stochastic Oscillator | 85.71 | 57.46 |
Price Performance
Historical ComparisonAbout ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.